Renal Artery Stenosis: Indications and Contraindications for Revascularization
Routine revascularization is not recommended for atherosclerotic renal artery stenosis—medical therapy is first-line for all patients, with revascularization reserved only for specific high-risk clinical scenarios that include refractory hypertension, progressive renal decline, or recurrent flash pulmonary edema. 1
Medical Management: First-Line for All Patients
Medical therapy is the cornerstone of treatment and must be optimized before any consideration of revascularization 1, 2:
- Thiazide diuretics at appropriate doses are a cornerstone agent 1, 2, 3
- Calcium channel blockers are highly effective and well-tolerated 1, 2, 3
- Beta-blockers may be added for additional blood pressure control 1, 2
- Statin therapy is essential given the atherosclerotic nature and high cardiovascular risk 1, 2, 3
- Low-dose aspirin for cardiovascular protection 1, 2, 3
- Intensive lifestyle modifications including sodium restriction to <1500 mg/day 3
Critical Medication Considerations
ACE inhibitors and ARBs:
- Safe and effective in unilateral stenosis 1, 2, 3
- Absolutely contraindicated in bilateral severe stenosis or stenosis of a solitary functioning kidney due to risk of acute renal failure from loss of efferent arteriolar tone 1, 2, 3, 4
- Monitor for serum creatinine rise >50% after initiation, especially in volume-depleted patients 2, 3
- 10-20% of patients develop unacceptable creatinine elevation, which typically reverts when treatment is withdrawn 1, 3
Absolute Contraindications to Revascularization
Do not revascularize:
- Uncomplicated unilateral atherosclerotic stenosis, even if anatomically severe (>70%) 1, 2
- Patients with adequate blood pressure control on medical therapy 1, 5
- Non-viable kidney: length <7 cm, cortical thickness <0.5 cm, albumin-creatinine ratio >30 mg/mmol, renal resistance index >0.8 1, 2, 4
- Long duration of hypertension (>10 years) predicts poor response 1, 3
Indications for Revascularization
Revascularization should be considered only when ALL of the following criteria are met 1, 2:
1. High-Risk Clinical Features (at least one required):
- Refractory/resistant hypertension: Diastolic BP >90 mmHg despite ≥3 antihypertensive drugs (including a diuretic at adequate doses), or uncontrolled on ≥5 drugs 1, 2, 6, 7, 8
- Progressive renal dysfunction: Rapidly declining renal function consistent with ischemic nephropathy 1, 2, 6, 7, 8
- Recurrent flash pulmonary edema or unexplained congestive heart failure with preserved left ventricular function 1, 6, 7, 8, 9
- Acute oligo-anuric renal failure with bilateral stenosis and kidney ischemia (rare indication) 1
- Fibromuscular dysplasia with hypertension or renal impairment 1, 2, 3, 6, 7
2. Anatomic Severity:
- Stenosis >60-75% confirmed by imaging 1, 6
- Bilateral severe stenosis or stenosis of a solitary functioning kidney with progressive dysfunction 1, 2, 4, 6, 8
3. Kidney Viability Criteria (all must be met):
- Kidney length >8 cm 1, 2, 4
- Cortical thickness >0.5 cm with distinct corticomedullary differentiation 1, 2, 4
- Albumin-creatinine ratio <20 mg/mmol (equivalent to protein-creatinine ratio <50 mg/mmol) 1, 2
- Renal resistance index <0.8 1, 2, 4
4. Optimal Medical Therapy Must Be Established First:
- Revascularization should never proceed until medical therapy has been maximized and proven inadequate 2, 5, 10
Technical Approach to Revascularization
Atherosclerotic Disease:
- Stenting is superior to balloon angioplasty alone for ostial atherosclerotic lesions, with procedural success rates of 96-100% versus 63-77% 1, 2, 3
- Stenting is recommended for ostial lesions 1
- Restenosis occurs in 15-24% of cases 3, 9
Fibromuscular Dysplasia:
- Balloon angioplasty alone is the treatment of choice, with bailout stenting only for complications 1, 2, 3, 4, 6, 7
- High rate of therapeutic success with persistent blood pressure normalization 1
Surgical Revascularization:
- Reserved for complex renal artery anatomy (aneurysms, branch vessel disease), failed endovascular procedures, or concomitant aortic surgery 1, 4, 6, 7
- 30-day mortality rates range from 3.7-9.4% 1
Expected Outcomes
Realistic expectations are critical:
- Cure of hypertension is rare (only 9-16% achieve diastolic BP ≤90 mmHg off all medications) 3, 7, 9
- Improved blood pressure control and reduced medication burden are more realistic goals 7, 9, 5
- Among patients with impaired baseline renal function: 20-30% improve, 40-60% stabilize, 20-30% deteriorate 3, 9
- Short duration of hypertension before intervention is the best predictor of effective blood pressure reduction 3, 7
- Post-hoc analysis suggests mortality benefit in patients without proteinuria 3
Critical Pitfalls to Avoid
- Never revascularize based solely on anatomic severity without confirming high-risk clinical features and kidney viability—this leads to unnecessary procedures with no clinical benefit 1, 2
- Never use ACE inhibitors or ARBs in bilateral severe stenosis or solitary kidney stenosis—this is an absolute contraindication that precipitates acute renal failure 1, 2, 3, 4
- Never proceed to revascularization before optimizing medical therapy—randomized trials demonstrate that medical management alone is effective for most patients 1, 5, 11, 12
- Do not revascularize non-viable kidneys—assess viability criteria before any intervention 1, 2, 4
Diagnostic Workup
- Duplex ultrasound is the first-line screening test, evaluating peak systolic velocity (PSV >200-300 cm/s), renal-aortic ratio (RAR >3.5), and resistive index 1, 2, 4
- CT angiography or MR angiography for confirmatory anatomic assessment when ultrasound is suggestive 1, 2, 4
- Selective renal angiography remains the gold standard when intervention is contemplated 3